Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Diabetics retinopathy remains the major threat to sight in the working age population in the
developed world. Furthermore, it is increasing as a major cause of blindness in other parts
of the world, especially developing countries. Diabetic macular edema (DME) is a
manifestation of diabetic retinopathy that produces loss of central vision.
The triamcinolone intravitreal injection (1-4mg) is indicated to treatment of diabetic
macular edema and it is considered an important treatment since it improves the visual acuity
of patients with resolution of edema.
Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription
eye drop (0.1% solution). Nepafenac is manufactured by Alcon as Nevanac. It is approved by
FDA as well as ANVISA. Pre-clinical studies suggest this medication showed efficacy to treat
ocular posterior segment inflammation.
The purpose of this study is evaluate the efficacy of intravitreal triamcinolone associated
with nepafenac eye drops as treatment of diabetic macular edema.